AvMed

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; <u>fax to 1-305-671-0200</u>. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. <u>If the information provided is not</u> complete, correct, or legible, the authorization process can be delayed.

Continuous Glucose Monitors (CGM)

Drug Requested: (Check below the CGM that applies, only <u>ONE</u> prior authorization form is required)

Formulary Preferred CGM's				
	FreeStyle Libre 14 Day System		FreeStyle Libre 2 System	
	(Reader/Sensors)		(Reader/Sensors/Plus Sensors)	
	Dexcom G6 [™] System		FreeStyle Libre 3 System	
	(Receiver/Transmitter/Sensors)		(Reader/Sensors/Plus Sensors)	
	Dexcom G7 [™] System			
	(Receiver/Transmitter/Sensors)			
Non-Formulary – Provider please note: A pharmacy medical necessity request form must be submitted for all Non-Formulary CGM requests				
	Eversense [®] (Sensor/Transmitter)		Guardian [™] 3 (Transmitter/Sensors)	
	Guardian [™] 4 (Transmitter/Sensors)			

<u>PROVIDER PLEASE NOTE</u>: Only one prior authorization form is required to be submitted for the request of any formulary or non-formulary CGM. If approved, an authorization will be entered for corresponding CGM supplies (e.g., readers, sensors, transmitters).

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name:		
Member AvMed #:		
Prescriber Name:		
Prescriber Signature:		
Office Contact Name:		
Phone Number:	Fax Number:	
NPI #:		

(Continued on next page)

Drug Form/Strength		
Dosing Schedule:	Length of Therapy:	
	ICD Code, if applicable: Date weight obtained:	
Weight (if applicable):		
• Will the member be discontinuing a previous the requested CGM?	sly prescribed continuous glucose monitor (CGM) if approved fo	
• If yes, please list the CGM that will be disco with the corresponding effective date.	ontinued and the CGM that will be initiated upon approval along	
Medication to be discontinued:	Effective date:	

Ouantity Limits:

Dexcom	<u>Freestyle</u>
 1 receiver per lifetime 3 sensors per 30 days 1 transmitter per 90 days 	 1 reader kit per lifetime 2 sensors per 28 days 2 plus sensors per 30 days

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

Continuous Glucose Monitors – Long Term Use

Length of Authorization: Indefinite

- □ Member requires Long-term CGM device indicated by <u>ALL</u> the following:
 - Diagnosis of <u>ONE</u> of the following:
 - **D** Type 1 Diabetes Mellitus
 - □ Type 2 Diabetes Mellitus
 - Gestational Diabetes

(Continued on next page)

- □ Member requires a demanding insulin regimen of at least three or more insulin injections per day or current use of an insulin pump
- □ Member or guardian consistently monitors blood glucose three or more times per day
- Provider attests that the member is motivated and knowledgeable about use of CGMs, is adherent to diabetic treatment plan, and participates in ongoing education and support

Continuous Glucose Monitors – Short Term Use

Length of Authorization: 1 month (30 days)

- □ Member requires Short-term CGM device indicated by <u>ALL</u> the following:
 - □ Diagnosis of <u>ONE</u> of the following:
 - □ Type 1 Diabetes Mellitus
 - □ Type 2 Diabetes Mellitus
 - **Gestational Diabetes**
 - □ Member must demonstrate at least <u>ONE</u> of the following:
 - Observed increase in blood glucose levels that takes place in the early morning (also known as The Dawn Phenomenon), known or suspected
 - □ Hypoglycemia unawareness (i.e., member does not have symptoms with hypoglycemia)
 - □ Nocturnal hypoglycemia, known or suspected
 - Destprandial hyperglycemia, known or suspected
 - □ Significant change to diabetes treatment regimen (e.g., initiation of insulin, change from multiple- dose insulin to insulin pump therapy)
 - □ Unexplained hyperglycemia
 - □ Member requires short term blood glucose monitoring (i.e., 7-14 days)

D Replacement Device

- □ Member has been previously approved for a CGM or insulin pump device
- □ At least <u>ONE</u> of the following problems have occurred which limits the use of the member's current CGM or insulin pump device
 - □ Abuse of equipment
 - □ Misuse of equipment
 - □ Reagent or instrument failure/defective devices
 - Defects in product design
 - □ Product instability
 - □ Failure to perform according to performance characterized in package insert
 - Incorrect test results (falsely elevated or decreased glucose results) that cause or contributed to an incorrect patient diagnosis and/or treatment

- □ Unexplained quality control (QC) failures
- □ Any other device problems that may compromise patient health or safety
- Provider or member must submit documentation that the member's current CGM or insulin pump device is not under warranty, including the date of warranty expiration

Not all drugs may be covered under every Plan

If a drug is non-formulary on a Plan, documentation of medical necessity will be required. **Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.** *<u>Previous therapies will be verified through pharmacy paid claims or submitted chart notes.</u>*